Search Results for: TP53

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
SRC SRC proto-oncogene, non-receptor tyrosine kinase
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Downregulation of ERBB4 signaling
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • Downstream signal transduction
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • G alpha (s) signalling events
  • G alpha (i) signalling events
  • G alpha (i) signalling events
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • RAF activation
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PTK2 signaling
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of RUNX1 Expression and Activity
  • RUNX2 regulates osteoblast differentiation
  • Regulation of RUNX3 expression and activity
  • Extra-nuclear estrogen signaling
  • Activated NTRK2 signals through FYN
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • Long-term potentiation
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric acid
  • Paratoulene phosphate
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • XL228
  • Tirbanibulin
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • PD-168393
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • PP-121
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Nintedanib
  • Fostamatinib
CDK7 cyclin dependent kinase 7
  • Formation of RNA Pol II elongation complex
  • Formation of the Early Elongation Complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Tat-mediated elongation of the HIV-1 transcript
  • NoRC negatively regulates rRNA expression
  • Formation of Incision Complex in GG-NER
  • RNA Polymerase II Pre-transcription Events
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of DNA Repair Genes
  • RNA polymerase II transcribes snRNA genes
  • RNA polymerase II transcribes snRNA genes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • mRNA Capping
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Phosphonothreonine
  • Alvocidib
  • SNS-032
  • Seliciclib
CCNH cyclin H
  • Formation of RNA Pol II elongation complex
  • Formation of the Early Elongation Complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Tat-mediated elongation of the HIV-1 transcript
  • NoRC negatively regulates rRNA expression
  • Formation of Incision Complex in GG-NER
  • RNA Polymerase II Pre-transcription Events
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of DNA Repair Genes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • mRNA Capping
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
MNAT1 MNAT1 component of CDK activating kinase
  • Formation of RNA Pol II elongation complex
  • Formation of the Early Elongation Complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Tat-mediated elongation of the HIV-1 transcript
  • NoRC negatively regulates rRNA expression
  • Formation of Incision Complex in GG-NER
  • RNA Polymerase II Pre-transcription Events
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of DNA Repair Genes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • mRNA Capping
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
HDAC1 histone deacetylase 1
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • G0 and Early G1
  • p75NTR negatively regulates cell cycle via SC1
  • Formation of the beta-catenin:TCF transactivating complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HDACs deacetylate histones
  • Notch-HLH transcription pathway
  • Deactivation of the beta-catenin transactivating complex
  • ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
  • NoRC negatively regulates rRNA expression
  • SUMOylation of chromatin organization proteins
  • Repression of WNT target genes
  • Repression of WNT target genes
  • Regulation of TP53 Activity through Acetylation
  • G1/S-Specific Transcription
  • RNA Polymerase I Transcription Initiation
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Estrogen-dependent gene expression
  • Loss of MECP2 binding ability to 5mC-DNA
  • Regulation of MECP2 expression and activity
  • MECP2 regulates neuronal receptors and channels
  • MECP2 regulates transcription of neuronal ligands
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Potential therapeutics for SARS
  • Factors involved in megakaryocyte development and platelet production
  • Arsenic trioxide
  • Zinc
  • Vorinostat
  • Belinostat
  • Pracinostat
  • Romidepsin
  • Panobinostat
  • Fingolimod
  • Mocetinostat
  • Abexinostat
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
SUMO1 small ubiquitin like modifier 1
  • SUMO is conjugated to E1 (UBA2:SAE1)
  • SUMO is transferred from E1 to E2 (UBE2I, UBC9)
  • SUMO is proteolytically processed
  • SUMOylation of DNA damage response and repair proteins
  • SUMO E3 ligases SUMOylate target proteins
  • SUMOylation of transcription factors
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • SUMOylation of transcription cofactors
  • SUMOylation of transcription cofactors
  • SUMOylation of SUMOylation proteins
  • SUMOylation of intracellular receptors
  • SUMOylation of intracellular receptors
  • SUMOylation of chromatin organization proteins
  • SUMOylation of chromatin organization proteins
  • SUMOylation of RNA binding proteins
  • SUMOylation of DNA replication proteins
  • SUMOylation of DNA replication proteins
  • SUMOylation of DNA methylation proteins
  • SUMOylation of DNA methylation proteins
  • SUMOylation of immune response proteins
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Nonhomologous End-Joining (NHEJ)
  • Processing of DNA double-strand break ends
  • Formation of Incision Complex in GG-NER
  • G2/M DNA damage checkpoint
  • Regulation of IFNG signaling
  • Negative regulation of activity of TFAP2 (AP-2) family transcription factors
  • Negative regulation of activity of TFAP2 (AP-2) family transcription factors
  • Postmitotic nuclear pore complex (NPC) reformation
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
UBE2D1 ubiquitin conjugating enzyme E2 D1
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • Inactivation of APC/C via direct inhibition of the APC/C complex
  • TICAM1, RIP1-mediated IKK complex recruitment
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Phosphorylation of the APC/C
  • APC-Cdc20 mediated degradation of Nek2A
  • Signaling by BMP
  • Downstream TCR signaling
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Separation of Sister Chromatids
  • Senescence-Associated Secretory Phenotype (SASP)
  • FCERI mediated NF-kB activation
  • CLEC7A (Dectin-1) signaling
  • Ovarian tumor domain proteases
  • CDK-mediated phosphorylation and removal of Cdc6
  • Transcriptional Regulation by VENTX
  • Synthesis of active ubiquitin: roles of E1 and E2 enzymes
  • E3 ubiquitin ligases ubiquitinate target proteins
  • Neddylation
  • Peroxisomal protein import
  • Negative regulators of DDX58/IFIH1 signaling
  • IKK complex recruitment mediated by RIP1
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
ERCC2 ERCC excision repair 2, TFIIH core complex helicase subunit
  • Formation of RNA Pol II elongation complex
  • Formation of the Early Elongation Complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Tat-mediated elongation of the HIV-1 transcript
  • Cytosolic iron-sulfur cluster assembly
  • NoRC negatively regulates rRNA expression
  • Formation of Incision Complex in GG-NER
  • Dual Incision in GG-NER
  • RNA Polymerase II Pre-transcription Events
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of DNA Repair Genes
  • mRNA Capping
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Disorders of nucleotide excision repair, including: Xeroderma pigmentosum (XP); Cockayne syndrome (CS); UV-sensitive syndrome (UVS); Trichothiodystrophy (TTD); Cerebro-oculo-facio-skeletal syndrome (COFS); XFE progeroid syndrome
RPA1 replication protein A1
  • Translesion synthesis by REV1
  • Recognition of DNA damage by PCNA-containing replication complex
  • Translesion Synthesis by POLH
  • Removal of the Flap Intermediate from the C-strand
  • Activation of ATR in response to replication stress
  • SUMOylation of DNA damage response and repair proteins
  • Regulation of HSF1-mediated heat shock response
  • HSF1 activation
  • Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • PCNA-Dependent Long Patch Base Excision Repair
  • Translesion synthesis by POLK
  • Translesion synthesis by POLI
  • Termination of translesion DNA synthesis
  • HDR through Single Strand Annealing (SSA)
  • HDR through Homologous Recombination (HRR)
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Formation of Incision Complex in GG-NER
  • Gap-filling DNA repair synthesis and ligation in GG-NER
  • Dual Incision in GG-NER
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • Fanconi Anemia Pathway
  • Regulation of TP53 Activity through Phosphorylation
  • Activation of the pre-replicative complex
  • Removal of the Flap Intermediate
  • G2/M DNA damage checkpoint
  • Meiotic recombination
UBE2I ubiquitin conjugating enzyme E2 I
  • Meiotic synapsis
  • Vitamin D (calciferol) metabolism
  • SUMO is transferred from E1 to E2 (UBE2I, UBC9)
  • SUMO is transferred from E1 to E2 (UBE2I, UBC9)
  • SUMOylation of DNA damage response and repair proteins
  • SUMO E3 ligases SUMOylate target proteins
  • SUMOylation of transcription factors
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • SUMOylation of transcription cofactors
  • SUMOylation of transcription cofactors
  • SUMOylation of SUMOylation proteins
  • SUMOylation of intracellular receptors
  • SUMOylation of intracellular receptors
  • SUMOylation of chromatin organization proteins
  • SUMOylation of chromatin organization proteins
  • SUMOylation of RNA binding proteins
  • SUMOylation of DNA replication proteins
  • SUMOylation of DNA replication proteins
  • SUMOylation of DNA methylation proteins
  • SUMOylation of DNA methylation proteins
  • SUMOylation of immune response proteins
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Processing of DNA double-strand break ends
  • Formation of Incision Complex in GG-NER
  • Negative regulation of activity of TFAP2 (AP-2) family transcription factors
  • Negative regulation of activity of TFAP2 (AP-2) family transcription factors
  • Postmitotic nuclear pore complex (NPC) reformation
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
ERCC3 ERCC excision repair 3, TFIIH core complex helicase subunit
  • Formation of RNA Pol II elongation complex
  • Formation of the Early Elongation Complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Tat-mediated elongation of the HIV-1 transcript
  • NoRC negatively regulates rRNA expression
  • Formation of Incision Complex in GG-NER
  • Dual Incision in GG-NER
  • RNA Polymerase II Pre-transcription Events
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of DNA Repair Genes
  • mRNA Capping
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Disorders of nucleotide excision repair, including: Xeroderma pigmentosum (XP); Cockayne syndrome (CS); UV-sensitive syndrome (UVS); Trichothiodystrophy (TTD); Cerebro-oculo-facio-skeletal syndrome (COFS); XFE progeroid syndrome
GTF2H1 general transcription factor IIH subunit 1
  • Formation of RNA Pol II elongation complex
  • Formation of the Early Elongation Complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Tat-mediated elongation of the HIV-1 transcript
  • NoRC negatively regulates rRNA expression
  • Formation of Incision Complex in GG-NER
  • Dual Incision in GG-NER
  • RNA Polymerase II Pre-transcription Events
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of DNA Repair Genes
  • mRNA Capping
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Pol II CTD phosphorylation and interaction with CE
GTF2H4 general transcription factor IIH subunit 4
  • Formation of RNA Pol II elongation complex
  • Formation of the Early Elongation Complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Tat-mediated elongation of the HIV-1 transcript
  • NoRC negatively regulates rRNA expression
  • Formation of Incision Complex in GG-NER
  • Dual Incision in GG-NER
  • RNA Polymerase II Pre-transcription Events
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of DNA Repair Genes
  • mRNA Capping
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Pol II CTD phosphorylation and interaction with CE
CDC42 cell division cycle 42
  • GPVI-mediated activation cascade
  • EGFR downregulation
  • Rho GTPase cycle
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • CD28 dependent Vav1 pathway
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • DCC mediated attractive signaling
  • Inactivation of CDC42 and RAC1
  • VEGFA-VEGFR2 Pathway
  • Myogenesis
  • Myogenesis
  • RHO GTPases activate KTN1
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAPK6/MAPK4 signaling
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • G beta:gamma signalling through CDC42
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Aminophosphonic acid-guanylate ester
  • Guanosine-5'-Diphosphate
CDK2 cyclin dependent kinase 2
  • G0 and Early G1
  • Telomere Extension By Telomerase
  • Activation of ATR in response to replication stress
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • Activation of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates Cell Cycle
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Factors involved in megakaryocyte development and platelet production
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3'-monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • (5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone
  • 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Alvocidib
  • (2E,3S)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'H)-one
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • N'-[4-(2,4-Dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-N-hydroxyimidoformamide
  • N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Seliciclib
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • 5-Bromoindirubin
  • (2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (5E)-2-Amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5H)-one
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • CAN-508
  • (2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • (2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • RO-4584820
  • N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide
  • N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide
  • 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
  • 4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide
  • 3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • AT-7519
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine
  • 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-Isopropyl-thiazol-2-YL)-2-pyridin-3-YL-acetamide
  • Variolin B
  • N(6)-dimethylallyladenine
CHUK component of inhibitor of nuclear factor kappa B kinase complex
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • AKT phosphorylates targets in the cytosol
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Constitutive Signaling by AKT1 E17K in Cancer
  • NIK-->noncanonical NF-kB signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Aminosalicylic acid
  • Mesalazine
  • Sulfasalazine
  • Acetylcysteine
  • Cocoon syndrome
GSK3B glycogen synthase kinase 3 beta
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • AKT phosphorylates targets in the cytosol
  • Regulation of HSF1-mediated heat shock response
  • CRMPs in Sema3A signaling
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • B-WICH complex positively regulates rRNA expression
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ubiquitin-dependent degradation of Cyclin D
  • Regulation of RUNX2 expression and activity
  • Replication of the SARS-CoV-1 genome
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
  • Replication of the SARS-CoV-2 genome
  • Lithium cation
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • SB-409513
  • AR-AO-14418
  • Staurosporine
  • Indirubin-3'-monoxime
  • 6-bromoindirubin-3'-oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • Fostamatinib
  • Tideglusib
  • Lithium citrate
  • Lithium succinate
  • Lithium carbonate
TBP TATA-box binding protein
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • SIRT1 negatively regulates rRNA expression
  • NoRC negatively regulates rRNA expression
  • B-WICH complex positively regulates rRNA expression
  • RNA Polymerase II Pre-transcription Events
  • Regulation of TP53 Activity through Phosphorylation
  • RNA polymerase II transcribes snRNA genes
  • RNA polymerase II transcribes snRNA genes
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase III Abortive And Retractive Initiation
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Polymerase III Transcription Initiation From Type 1 Promoter
  • RNA Polymerase III Transcription Initiation From Type 1 Promoter
  • RNA Polymerase III Transcription Initiation From Type 2 Promoter
  • RNA Polymerase III Transcription Initiation From Type 2 Promoter
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • Estrogen-dependent gene expression
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
PLK1 polo like kinase 1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Polo-like kinase mediated events
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Phosphorylation of the APC/C
  • Phosphorylation of Emi1
  • Condensation of Prophase Chromosomes
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Regulation of PLK1 Activity at G2/M Transition
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • Mitotic Metaphase/Anaphase Transition
  • Mitotic Telophase/Cytokinesis
  • Cyclin A/B1/B2 associated events during G2/M transition
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • EML4 and NUDC in mitotic spindle formation
  • 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol
  • 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide
  • 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
  • 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea
  • Wortmannin
  • Fostamatinib

Page 2 out of 25 pages